Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohns disease
ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and…
Longer-term data for Novartis Scemblix reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML
Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs…